MAIN CONFERENCE DEC. 16 - PT (Pacific Time, GMT-08:00)
- Jyothsna Visweswaraiah, PhD - Director, Biotherapeutics Drug Creation, Seismic Therapeutic
- Sara Colombetti, PhD - Global Head of Oncology Discovery Pharmacology, Roche Innovation Center Zürich
The talk will focus on our pre-clinical and clinical experience with CD27 monoclonal antibodies and consider how their therapeutic activity might be improved.
- Sean Lim, Ph.D. - Professor of Haematology & Translational Immunolog, University of Southampton
A recent clinical trial involving MOv18 IgE, provided tantalising evidence of IgE’s potential for the treatment of cancer. Epsilogen is conducting a phase Ib trial in which translational data will be collated to further understand mechanisms associated with IgE therapy. In addition, Epsilogen has established a pipeline of anti-tumoral IgEs and two novel platforms: bispecific IgE and a hybrid antibody which combines the effector functions of IgE and IgG.
- Kevin Fitzgerald, PhD. - Chief Scientific Officer, Epsilogen
The FORCE™ platform was designed to enhance delivery of oligonucleotide to muscle for the treatment of neuromuscular disorders by conjugating them to an antigen-binding fragment (Fab) that is selective for the human transferrin receptor 1 (TfR1). In this presentation, we introduce the properties and modularity of the FORCE platform and provide evidence of translation between pre-clinical models and clinical proof of concept in myotonic dystrophy type 1 (DM1) with DYNE-101.
- Tama Evron, Ph.D - Director, Platform Discovery, Dyne Therapeutics
- Christine Moussion, PhD - Senior Principal Scientist and Group Head, Cancer Immunotherapy Discovery, Genentech
We show unique mechanisms of flexible homodimerization crucial for the inhibitory function of checkpoint receptor PD-1 and LAG-3, and identified a novel cell surface receptor potently modulating myeloid-associated Type-I IFN responses. These efforts laid the foundation for developing novel immunotherapies for cancer and autoimmune diseases.
- Jun Wang, Ph.D. - Assistant Professor, Department of Pathology, NYU Grossman School of Medicine
- Sara Colombetti, PhD - Global Head of Oncology Discovery Pharmacology, Roche Innovation Center Zürich